Newspaper icon
The latest issue of Financial Standard now available as an e-newspaper
READ NOW

Search Results

Showing 111 - 120 of 120 results for "Biotech"

Solid 2004 for Intersuisse small caps index

AAP  |  FRIDAY, 14 JAN 2005
... with a number of US cities. Another six companies doubled their prices during the year with property manager Breakfree, biotech pSivida, shipbuilder Austal, Commander Communications and Tomato Technologies each achieving at least 100 per cent gains. ...

Record IPO Activity: It's crazy out there says Deloitte

Deloitte's latest IPO report has revealed a record breaking year for IPOs with an unprecedented 176 newly floated companies raising a total of $10.4 billion. "It's crazy out there. It's hard to tell whether we're at the top of the cycle but the next ...

Queensland BioCapital Funds goes to Colledge for CEO

Queensland BioCapital Funds (QBF), the $100 million strong closed-end venture capital that invests in the human biosciences sector, has appointed Neill Colledge as its new chief executive officer. He joins QBF after performing a role as senior portfolio ...

Intersuisse says biotechs performing best since 2000

AAP  |  TUESDAY, 6 JUL 2004
... performing at their best since the technology boom of 2000, brokerage Intersuisse said today. Intersuisse said share prices for biotech companies had risen 24% to the year to June 2004, outperforming the All Ordinaries Index which lifted 18%, and the ...

BT appoints new portfolio manager

... joined BT having worked as head of emerging companies research team at JP Morgan and previously director of technology, biotech and healthcare research at Deutsche.

Biota to sue GlaxoSmithKline over Relenza flu drug

AAP  |  WEDNESDAY, 5 MAY 2004
Biotech Biota Holdings is suing global pharmaceutical giant GlaxoSmithKline, alleging that GSK failed to support and promote Biota's flu drug, Relenza. Biota said it had issued a writ in the Victorian Supreme Court. Biota, which licensed Relenza to ...

Healthcare, biotechs seen as best Australian investments

AAP  |  FRIDAY, 23 JAN 2004
Australia's healthcare and biotechnology sectors offered the best opportunities for investment, a prominent United States investor told a gathering in Los Angeles last week. Tom Lynch, managing director of Wilshire Associates' Private Equity Group ...

Morning Market Wrap: Lacklustre lead from US; Dollar starts strong

... pushed shares in health group Amersham 15.2 per cent higher, boosting sector mate Smith & Nephew by 4.4 per cent and midcap biotech Celltech by 5.6 per cent. The FTSE 100 index closed 2.9 points lower at 4311.0, back from 4,327.0 but finishing above ...

ABS releases third survey on venture capital trends

The Australian Bureau of Statistics (ABS) today released the results of its third venture capital survey, indicating further strong growth occurring during 2001-02. The ABS said that as at June 30 2002, investors had $6.9 billion committed to venture ...

Babcock and Brown purchases $2.5 million of Biotech shares

... believe that Biota is now in a strong position to play a leading role in the necessary consolidation of the Australian biotech industry, and this investment represents our vote of support for the company and its strategy," he added.